Meta‐analysis: Real‐world effectiveness and safety of ustekinumab in patients with ulcerative colitis

P383 Ustekinumab as an opportunity for refractory Ulcerative Colitis patients

(2022) M Iborra et al.   Journal of Crohns & Colitis

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS

(2022) L Albino et al.   Journal of the Canadian Association of Gastroenterology

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

(2022) Maria T Abreu et al.   Journal of Crohns & Colitis

Ustekinumab treatment in ulcerative colitis: Real‐world data from the Swedish inflammatory bowel disease quality register

(2022) Joel Thunberg et al.   United European Gastroenterology Journal

Real-World Evidence of the Effectiveness and Safety of Ustekinumab for the Treatment of Crohn’s Disease: Systematic Review and Meta-Analysis of Observational Studies

(2022) Cristina Rubín de Célix et al.   Journal of Clinical Medicine

Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial

(2021) William J. Sandborn et al.   Clinical Gastroenterology and Hepatology

Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis

(2021) Carlos Taxonera et al.   INFLAMMATORY BOWEL DISEASES

Predictors and Outcomes of Ustekinumab Dose Intensification in Ulcerative Colitis: A Multicenter Cohort Study

(2021) Rahul S. Dalal et al.   Clinical Gastroenterology and Hepatology

Sa555 COLECTOMY-FREE DRUG SURVIVAL OF USTEKINUMAB IN ULCERATIVE COLITIS: A REAL-WORLD, MULTICENTER COHORT STUDY IN THE UNITED STATES

(2021) Rahul S. Dalal et al.   GASTROENTEROLOGY

Real-World Comparison of Tofacitinib vs Ustekinumab Among Bio-Exposed Patients With Ulcerative Colitis: A Propensity Score Analysis

(2021) Rahul S Dalal et al.   INFLAMMATORY BOWEL DISEASES

Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study

(2021) Mathurin Fumery et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

One-year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicenter real-world study from Italy

(2021) Michele Francesco Chiappetta et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study

(2020) Aurélien Amiot et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Relationship Between Combined Histologic and Endoscopic Endpoints and Efficacy of Ustekinumab Treatment in Patients With Ulcerative Colitis

(2020) Katherine Li et al.   GASTROENTEROLOGY

Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2019) Bruce E. Sands et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis

(2019) Thomas Ochsenkühn et al.   United European Gastroenterology Journal

Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease

(2018) Stefan Schreiber et al.   JOURNAL OF GASTROENTEROLOGY

Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis

(2017) Carlos Taxonera et al.   INFLAMMATORY BOWEL DISEASES

Adalimumab Maintenance Treatment in Ulcerative Colitis: Outcomes by Prior Anti-TNF Use and Efficacy of Dose Escalation

(2016) Carlos Taxonera et al.   DIGESTIVE DISEASES AND SCIENCES

Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease

(2016) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target

(2015) L Peyrin-Biroulet et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

(2013) Brian G. Feagan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population

(2012) Christina Ha et al.   Clinical Gastroenterology and Hepatology